Company news
Tempest Therapeutics, Inc. news in 2023
Tempest Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
November 7, 2023
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
October 10, 2023
Tempest Adopts Limited Duration Stockholder Rights Plan
October 10, 2023
Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
September 18, 2023
Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update
August 9, 2023
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
July 18, 2023
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
May 24, 2023
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update
May 9, 2023
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 27, 2023
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
April 26, 2023
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
April 25, 2023
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
April 16, 2023
Tempest Reports Year End 2022 Financial Results and Provides Business Update
March 21, 2023